Tran A, Retnakaran R, Zinman B, Kramer CK
Gastrointestinal Adverse Events GI AEs are the most frequently reported side effects of GLP-1 RAs and, although typically mild, moderate, and transient, they remain the primary reason for treatment discontinuation among individuals with obesity receiving semaglutide [13, 27, 38, 40,41,42,43,44,45,46, 52]
Results Statistical and molecular modelling analyses confirmed that the use of several registered drugs, including acetylsalicylic acid and atenolol may be associated with inhibition of Glutathione Peroxidase 1 and chronic obstructive pulmonary disease
A plan that excludes weight-loss drugs can still cover Zepbound for OSA the diagnosis, not the benefit election, is the gate
[See Contraindications
Singleton, C.K